Acadian Asset Management LLC Kazia Therapeutics LTD Transaction History

Acadian Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.84 - $1.17 $41,615 - $57,964	-49,542 Reduced 72.62%	18,682 $18,000
Q1 2023 May 11, 2023	SELL	$0.73 - $1.16 $26,242 - $41,700	-35,949 Reduced 34.51%	68,224 $70,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.23 $31,607 - $77,753	-63,214 Reduced 37.77%	104,173 $64,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $4.19 $184,125 - $701,351	167,387 New	167,387 $183,000
Q4 2020 Feb 11, 2021	SELL	$5.61 - $13.47 $5,307 - $12,742	-946 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$3.33 - $8.26 $3,150 - $7,813	946 New	946 $6,000
Q4 2018 Feb 07, 2019	SELL	$2.2 - $3.18 $5,238 - $7,571	-2,381 Closed	0 $0
Q3 2018 Oct 30, 2018	SELL	$3.05 - $3.9 $17,446 - $22,308	-5,720 Reduced 70.61%	2,381 $8,000
Q1 2018 Apr 12, 2018	BUY	$2.88 - $6.25 $23,330 - $50,631	8,101 New	8,101 $45,000

2.13M

93.2K

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $82.5M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.